ArticleEmerging microbes & infections2023
The nasopharyngeal microbiome in COVID-19.
Article in Emerging microbes & infections, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 39 citations in OpenAlex.
- Human bronchopulmonary disposition and plasma pharmacokinetics of oral bemnifosbuvir (AT-527), an experimental guanosine nucleotide prodrug for COVID-19.The Journal of antimicrobial chemotherapy · 2024Trial
- SARS-CoV-2 Infection disrupts lower respiratory tract microbiome function and interactions.BMC microbiology · 2026Article
- Non-pharmaceutical interventions restructured the upper respiratory bacterial microbiota in children under 2 during COVID-19: implications for infection control strategies.Frontiers in microbiology · 2026Article
- Microbiome and Long COVID-19: Current Evidence and Insights.International journal of molecular sciences · 2025Review
- Article
- Impact of SARS-CoV-2 P.1 Variant Infection on the Nasopharyngeal Commensal Bacterial Microbiome of Individuals from the Brazilian Amazon.Microorganisms · 2025Article
- Age- and disease severity-associated changes in the nasopharyngeal microbiota of COVID-19 patients.iScience · 2025Article
- The relationship between gut and nasopharyngeal microbiome composition can predict the severity of COVID-19.eLife · 2025Observational
- Pathogenic and periodontal bacteria may contribute to the fatal outcome of critically ill elderly COVID-19 patients.Scientific reports · 2025Article
- Clinical relevance of lung microbiota composition in critically ill children with acute lower respiratory tract infections: insights from a retrospective analysis of metagenomic sequencing.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- The Human Nasal Microbiome: A Perspective Study During the SARS-CoV-2 Pandemic in Malta.Microorganisms · 2024Article
- The Silent Syndrome of Long COVID and Gaps in Scientific Knowledge: A Narrative Review.Viruses · 2024Review
- Influence of Mycobiota in the Nasopharyngeal Tract of COVID-19 Patients.Microorganisms · 2024Article
- Metagenomic next-generation sequencing of nasopharyngeal microbiota in COVID-19 patients with different disease severities.Microbiology spectrum · 2024Article
- Alterations in microbiota of patients with COVID-19: implications for therapeutic interventions.MedComm · 2024Review
- Oropharyngeal Microbiome Analysis in Patients with Varying SARS-CoV-2 Infection Severity: A Prospective Cohort Study.Journal of personalized medicine · 2024Article
- Exploring nasopharyngeal microbiota profile in children affected by SARS-CoV-2 infection.Microbiology spectrum · 2024Article
- The Microbiota in Long COVID.International journal of molecular sciences · 2024Review
- Changes in the ocular surface microbiome of patients with coronavirus disease 2019 (COVID-19).Frontiers in microbiology · 2024Article
- Disentangling the interactions between nasopharyngeal and gut microbiome and their involvement in the modulation of COVID-19 infection.Microbiology spectrum · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of novel culture-independent techniques of microbial identification has allowed a rapid progress in the knowledge of the nasopharyngeal microbiota and its role in health and disease. Thus, it has been demonstrated that the nasopharyngeal microbiota defends the host from invading pathogens that enter the body through the upper airways by participating in the modulation of innate and adaptive immune responses. The current COVID-19 pandemic has created an urgent need for fast-track research, especially to identify and characterize biomarkers to predict the disease severity and outcome. Since the nasopharyngeal microbiota diversity and composition could potentially be used as a prognosis biomarker for COVID-19 patients, which would pave the way for strategies aiming to reduce the disease severity by modifying such microbiota, dozens of research articles have already explored the possible associations between changes in the nasopharyngeal microbiota and the severity or outcome of COVID-19 patients. Unfortunately, results are controversial, as many studies with apparently similar experimental designs have reported contradictory data. Herein we put together, compare, and discuss all the relevant results on this issue reported to date. Even more interesting, we discuss in detail which are the limitations of these studies, that probably are the main sources of the high variability observed. Therefore, this work is useful not only for people interested in current knowledge about the relationship between the nasopharyngeal microbiota and COVID-19, but also for researchers who want to go further in this field while avoiding the limitations and variability of previous works.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.